Entrada Therapeutics Revenue and Competitors

Boston, MA USA

Location

#6939

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Entrada Therapeutics's estimated annual revenue is currently $19.5M per year.(i)
  • Entrada Therapeutics's estimated revenue per employee is $123,608
  • Entrada Therapeutics's total funding is $175.6M.

Employee Data

  • Entrada Therapeutics has 158 Employees.(i)
  • Entrada Therapeutics grew their employee count by 44% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.2M10%N/AN/A
#3
$4.2M2735%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$1.4M929%N/AN/A
#6
$235M255-31%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.3M340%N/AN/A
#10
$1.9M12-8%N/AN/A
Add Company

Entrada Therapeuticsᅢᄁ¬ツᆲ¬トᄁ mission is to treat devastating diseases by developing intracellular biologics. Using its proprietary EEVᅢᄁ¬ダᅡᄁ technology, Entrada is creating a diverse pipeline of enzyme, oligonucleotide, protein and peptide programs to efficiently engage intracellular disease targets across multiple therapeutic areas. The Companyᅢᄁ¬ツᆲ¬トᄁs novel approach addresses current challenges associated with both large and small molecule therapeutics and represents a fundamental advancement in the field of intracellular biologics. Entrada, a privately-held company, raised $59 million in a Series A financing in December 2018. The financing was co-led by 5AM Ventures and MPM Capital, along with Roche Venture Fund, MRL Ventures Fund and Agent Capital. For more information, please visit www.entradatx.com.

keywords:N/A

$175.6M

Total Funding

158

Number of Employees

$19.5M

Revenue (est)

44%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Entrada Therapeutics News

2022-04-17 - Movers & Shakers: John Maraganore, Larry Alstiel, Brad Margus ...

Alstiel is currently a part-time CMO at Pinteon Therapeutics. ... Alaunos Therapeutics, Homology Medicines, Entrada Therapeutics, Enterome,...

2022-04-17 - Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Lock-Up Period Will ...

Entrada Therapeutics had issued 9,075,000 shares in its initial public offering on October 29th. The total size of the offering was $181,500,000...

2022-03-30 - Scrambling for Talent and More Office Space, Life Sciences ...

Entrada, an intracellular therapeutics company currently located on Tide Street in Boston, is moving just down the street. The company is...

2021-03-31 - Entrada Therapeutics Closes $116M Series B Financing

Entrada Therapeutics Inc., a Boston, MA-based biotechnology company dedicated to advancing treatment of devastating diseases using intracellular biologics, closed a $116m Series B financing. The round was led by Wellington Management Company. Wellington Management was joined by Redmile Group, T ...

2021-03-31 - Entrada Therapeutics Announces Closing of $116 Million Series B Financing

Entrada Therapeutics Inc., a privately-held biotechnology company dedicated to transforming the treatment of devastating diseases using intracellular biologics, today announced the successful completion of a $116 million Series B financing. The Series B financing was led by Wellington Managemen ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$38.2M1589%N/A
#2
$35M158-3%N/A
#3
N/A15844%N/A
#4
$43.7M15916%N/A
#5
$39.7M1592%N/A